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Abstract
Background: Rapid molecular diagnostics, with their ability to quickly identify genetic mutations associated with
drug resistance in Mycobacterium tuberculosis clinical specimens, have great potential as tools to control multi- and
extensively drug-resistant tuberculosis (M/XDR-TB). The Qiagen PyroMark Q96 ID system is a commercially available
pyrosequencing (PSQ) platform that has been validated for rapid M/XDR-TB diagnosis. However, the details of the
assay’s diagnostic and technical performance have yet to be thoroughly investigated in diverse clinical
environments.
Methods: This study evaluates the diagnostic performance of the PSQ assay for 1128 clinical specimens from
patients from three areas of high TB burden. We report on the diagnostic performance of the PSQ assay between
the three sites and identify variables associated with poor PSQ technical performance.
Results: In India, the sensitivity of the PSQ assay ranged from 89 to 98 % for the detection of phenotypic resistance
to isoniazid, rifampicin, fluoroquinolones, and the injectables. In Moldova, assay sensitivity ranged from 7 to 94 %,
and in South Africa, assay sensitivity ranged from 71 to 92 %. Specificity was high (94–100 %) across all sites. The
addition of eis promoter sequencing information greatly improved the sensitivity of kanamycin resistance detection
in Moldova (7 % to 79 %). Nearly all (89.4 %) sequencing reactions conducted on smear-positive, culture-positive
specimens and most (70.8 %) reactions conducted on smear-negative, culture-positive specimens yielded valid PSQ
reads. An investigation into the variables influencing sequencing failures indicated smear negativity, culture
negativity, site (Moldova), and sequencing of the rpoB, gyrA, and rrs genes were highly associated with poor PSQ
technical performance (adj. OR > 2.0).
Conclusions: This study has important implications for the global implementation of PSQ as a molecular TB
diagnostic, as it demonstrates how regional factors may impact PSQ diagnostic performance, while underscoring
potential gene targets for optimization to improve overall PSQ assay technical performance.
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Background
In 2014, 9.6 million new cases of tuberculosis (TB) and
1.5 million TB-associated deaths were reported world-
wide [1]. Although the incidence of new TB cases has
continued to fall over the past decade, the incidence of
multi- and extensively drug-resistant TB (M/XDR-TB)
has been stable, undermining TB eradication efforts.
MDR-TB is defined as TB that has developed resistance
to the first-line anti-tuberculosis drugs isoniazid (INH)
and rifampicin (RIF). XDR-TB is MDR-TB that has de-
veloped additional resistance to the fluoroquinolones
(FQs) and at least one of the injectable compounds
[amikacin (AMK), kanamycin (KAN) and/or capreomy-
cin (CAP)]. An estimated 480,000 people developed
MDR-TB while 190,000 deaths were attributed to MDR-
TB in 2014 [1]. Alarmingly, only 26 % of the estimated
MDR-TB infections globally were detected in 2014 [1].
This means that over one third of a million people suf-
fered from undiagnosed and untreated drug-resistant
TB, which is a significant risk for high mortality and
continued transmission of M/XDR-TB.
The conventional methodology for diagnosis of drug-
resistant TB (DR-TB) has not changed for decades, and
relies upon mycobacterial culture and drug susceptibility
testing (DST) in solid or liquid media. These methods
yield results only after weeks to months of cell culture,
and require biosafety conditions that are complex and
expensive to implement in low- and middle-income
countries. MDR- and XDR-TB patients waiting for
growth-based diagnostic test results before appropriate
treatment is started remain contagious and at increased
risk of death.
Rapid molecular diagnostics for M/XDR-TB have great
potential to shorten the time to DR-TB diagnosis and
appropriate treatment. Pyrosequencing (PSQ) is a real
time, rapid method for sequencing fragments of genomic
DNA. PSQ assays have been previously established as
valid technologies to rapidly and accurately identify mu-
tations associated with drug resistance in Mycobacterium
tuberculosis (Mtb) isolates and in clinical specimens [2–
8]. The commercially available Qiagen PyroMark Q96
PSQ platform has been validated as an M/XDR-TB diag-
nostic assay and is currently in use in by the Microbial
Diseases Laboratory in the California Department of
Public Health for rapid detection of M/XDR-TB in the
United States, having been validated for clinical use [9,
10]. One study validating this PSQ assay against conven-
tional methods in high burden settings found strong cor-
relations with phenotypic DST, with sensitivity values
ranging from 86 to 100 % and specificity values ranging
from 99 to 100 % for all drugs tested [9]. The Global
Consortium for Drug-resistant TB Diagnostics (GCDD)
also conducted a large-scale, multisite study to evaluate
the ability of this assay to accurately predict TB
phenotypic drug resistance profiles, and found test per-
formance to vary across diverse clinical environments.
Overall assay sensitivity ranged from 50 to 95 %, and the
number of interpretable results ranged from 73 to 88 %
among Mtb culture-positive specimens [11]. These varia-
tions highlight potential limitations of the assay. This
study examines the detailed diagnostic and technical
performance of a PSQ assay for M/XDR-TB diagnosis in
three diverse clinical sites and describes modifications
that could improve overall diagnostic and technical per-
formance of the PSQ assay.
Methods
Study population
Briefly, three diverse clinical sites (Chisinau, Moldova,
Port Elizabeth, South Africa, and Mumbai, India) were
selected for this study [12]. Newly-presenting TB pa-
tients over 5 years of age were eligible for the study if
they were known to be acid-fast bacilli (AFB) smear-
positive (defined as 1+ or greater within prior 14 days)
or suspected of having active pulmonary TB and having
one or more reason to be considered to have DR-TB,
and provided informed consent for the study. Patients
unable to provide 7.5 mL of sputum were excluded,
along with subjects who had second-line DST in the
prior three months. A total of 1128 patients meeting the
above criteria were enrolled in the GCDD study from
April 24, 2012 to June 27, 2013.
Acid-Fast Bacilli (AFB) smear and drug-susceptibility
testing
AFB smear testing was performed on all isolates, and
smear grading was determined in the first 2 weeks fol-
lowing enrollment. All phenotypic drug susceptibility
profiles were established using the Mycobacterial
Growth Indicator Tube (MGIT) 960 platform. These
MGIT DST results served as reference standard in our
study. All specimens were tested for resistance to INH,
RIF, two FQs [moxifloxacin (MOX) and ofloxacin
(OFX)], and three injectable drugs (AMK, KAN and
CAP) using standard manufacturer protocols [13] and
previously-published and World Health Organization-
recommended critical concentrations for MGIT-based
DST [12, 14].
DNA extraction, PCR and molecular targets
Crude DNA was extracted from each decontaminated,
concentrated sputum (sediment) by heating the cell sus-
pensions in a water bath at 100 °C [9, 12]. PCR master
mixes were prepared and amplification reactions were
carried out as previously reported [9]. Table 1 lists all
primers used for PCR and sequencing reactions. Our
PSQ assay included one reaction to identify Mtb and
seven reactions to detect specific mutations in drug
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resistance-associated gene regions. The molecular target
IS6110 was considered confirmatory for identification of
Mtb. However, since the marker is not 100 % reliable, es-
pecially for Indian strains of Mtb [15–19], we included
findings for specimens deemed indeterminate for pres-
ence of the IS6110 marker via PSQ as long as at least
one other Mtb gene yielded a sequencing result. This
practice is in accordance with similar PSQ studies as,
apart from the rrs, the primers utilized in sequencing re-
actions are highly specific for Mtb [9]. A negative H2O
control was used for every target in each run.
Pyrosequencing (PSQ)
We used the PyroMark Q96 ID system (Qiagen, Valencia,
CA) to perform PSQ on specific regions of the ahpC and
inhA promoters and the katG, rpoB, gyrA, and rrs genes,
sequencing two different parts of rpoB in two separate re-
actions, as described previously [9]. Sequencing of these
targets was completed at the respective clinical sites. Se-
quenced gene regions are outlined in Table 1. Variants
relative to the Mtb H37Rv reference strain (ATCC 27294)
were identified automatically from generated PSQ pyro-
grams using IdentiFire software (Qiagen, Valencia, CA).
All samples that did not provide PSQ queries with a
100 % match to library wildtype or mutant sequences were
repeated in duplicate. Samples that still did not provide
confirmatory sequence and samples for which contradict-
ory hits were obtained for any given target were deemed
genotypically indeterminate.
Upon completion of the study, eis promoter sequen-
cing capabilities were added to the platform by designing
primers specific for sequencing the eis promoter of Mtb
(Table 1), and updating the system’s library for query
read identification via the IdentiFire software. eis se-
quencing reactions used PCR and PSQ parameters iden-
tical to the other assay targets. In sequencing the eis
promoter, DNA extracted from specimens from India
were sequenced on-site, while DNA extracted from
specimens from Moldova and South Africa were se-
quenced using a PyroMark Q96 ID system at the Uni-
versity of California, San Diego. As for the other targets,
all eis queries that did not 100 % match reference library
sequences were repeated in duplicate.
Pyrosequencing (PSQ) diagnostic performance
In order to comment on the validity of the PyroMark
PSQ platform in establishing Mtb drug resistance pro-
files, we calculated sensitivity and specificity for each
drug by comparing PyroMark findings to conventional
MGIT phenotypic DST results in each clinical site. Only
those specimens with both sequencing results and DST
results for the relevant drugs of interest were included
in diagnostic performance estimate calculations. Sensi-
tivity was calculated as the number of phenotypically re-
sistant specimens in which a resistance-associated
mutation was found via PSQ, divided by the number of
phenotypically resistant specimens. Specificity was calcu-
lated as the number of phenotypically susceptible speci-
mens in which no resistance-associated mutation was
found via PSQ, divided by the number of phenotypically
susceptible specimens. INH resistance was determined
with PSQ via the presence of known resistance-
Table 1 Primers Utilized in PCR and Pyrosequencing (PSQ) Reactions
Genes Target Forward primer Reverse primer Sequencing primer Detection
range
Reference
Mtb
Identification
IS6110 Biotin-CCGCCAACTACGGTGTTTA CAGGCCGAGTTTGGTCAT GGCCACCTCGATGCC Multiple [9]
Isoniazid-R katG Biotin-CGGAACCGGTAAGGACGC CCATTTCGTCGGGGTGTTC TCCATACGACCTCGAT Codons 312
to 316
[9]
inhA Biotin-ACGCTCGTGGACATACCG CAGTGGCTGTGGCAGTCA TGTGGCAGTCACCCC Position −4
to −20
[9]
ahpC TCCTCATCATCAAAGCGGACAAT Biotin-
CGATGCCGATAAATATGGTGTGAT
CATTTGGTTGCGACAT Position −4
to −23
[9]
Rifampin-R rpoB1 GGAGGCGATCACACCGCAGACGTT Biotin-
CCTCCAGCCCGGCACGCTCACGT
GCGATCAAGGAGTTCTTC Codons 507
to 521
[6, 9]
rpoB2 TTTCGATCACACCGCAGACGTT Biotin-
AAAGGCACGCTCACGTGACAGAC
CAGAACAACCCGCTG Codons 522
to 533
[6, 9]
Fluoroquinolone-
R
gyrA AATGTTCGATTCCGGCTTCC Biotin-CGGGCTTCGGTGTACCTCAT CAACTACCACCCGCAC Codons 88
to 95
[2]
Injectable-R rrs TAAAGCCGGTCTCAGTTCGGAAaC Biotin-
CAGCTCCCTCCCGAGGGTTA
CTTGTACACACCGCC Position 1397
to 1406
[9]
Kanamycin-R eis Biotin-
GGCTACACAGGGTCACAGTC
GCCAGACACTGTCGTCGTAATATTC CAGACACTGTCGTCG Position −5
to −47
This
study
a“A” was substituted for “T” in the natural sequence to improve specificity
Mtb Mycobacterium tuberculosis, −R -resistant
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conferring mutations in at least one of three genes
(inhA, katG and ahpC), RIF resistance through presence
of at least one resistance-associated mutation in one of
two rpoB gene regions, injectable resistance through the
presence of the 1401G or 1402T mutation in the rrs
gene, and FQ resistance via the presence of resistance-
conferring mutations in the gyrA gene. KAN resistance
was determined via the presence of the 1401G or 1402T
mutation in the rrs gene or the presence of a resistance-
associated mutation in the eis promoter. Confidence in-
tervals for sensitivity and specificity of individual muta-
tions were determined using the score/efficient score
method with continuity correction [20, 21]. Diagnostic
performance differences were noted between the sites
based upon the presence of non-overlapping confidence
intervals for sensitivity or specificity calculations for any
particular drug.
Analysis of pyrosequencing (PSQ) technical performance
Sequencing success was first determined for smear- and
culture-negative and positive samples by calculating the
proportion of the total PSQ reactions conducted for
those samples that yielded interpretable sequencing re-
sults. The variables associated with poor PSQ technical
performance, defined as the inability to obtain interpret-
able sequencing results, were then investigated by logis-
tic regression, using STATA 13.1 Software (StataCorp,
College Station, TX, USA). The outcome variable was an
“indeterminate” result, or the inability to obtain a PSQ
read that generated a 100 % match with a target library
sequence. Covariates evaluated included: smear negativ-
ity, culture negativity, clinical site and gene target. A bi-
variate analysis was first conducted to generate
unadjusted odds ratios for each variable. Variables with
p-value <0.20 were considered for inclusion in the final
model. Covariates included in the final multivariate
model with p-value <0.05 were considered significant.
In order to further comment on the underlying rea-
sons for PSQ failures, all indeterminate results were cat-
egorized according to type of observed error. Categories
included: no read error, homopolymer error, instrument
error, mixed population, new mutation, or other error.
No read errors were defined as unresolved errors where
few or no peaks were seen in the resulting PSQ pyro-
grams in all sequencing reactions for a given gene target.
Homopolymer errors were unresolved errors that oc-
curred due to IdentiFire software mischaracterization of
pyrogram peak height at one or more bases in any PSQ
reaction for a given gene target. Instrument errors were
unresolved errors resulting from incorrect instrument
reagent dispensation or camera detection errors, where
one or more peaks in the resulting pyrogram were seen
as a split peak (two small peaks) below IdentiFire peak
detection threshold. Mixed populations occurred when
all three pyrograms obtained for any gene target were
identical but did not match a confirmatory sequence in
the sequencing library due to the presence of two peaks
in a given mutation region- representing both wildtype
and mutant sequences. New or novel mutations were
confirmed when three unambiguous, identical pyro-
grams were obtained for any gene target but did not
match a sequence in the reference sequence library of
known wildtype and common mutations in that region.
Finally, the other error category included all other er-
rors, including unknown errors or a combination of
error types that could not be attributed to a single
source. All PSQ indeterminates were characterized ac-
cording to one of these reasons for error, and the num-
bers of errors falling into the different categories were
summarized for each gene target.
Human research conduct
Our study was approved by the Institutional Review
Board of the University of California, San Diego and by
the Institutional Review Boards of the respective clinical
sites.
Results
Culture and Drug Susceptibility Testing (DST) results
Of 1128 patients enrolled in the study, 914 (81 %) pro-
vided Mtb culture-positive pulmonary sputum samples.
One of the remaining 214 samples was contaminated,
and the rest were Mtb culture-negative. MGIT DST
could not be performed, or did not yield results, for
seven of the 914 culture-positive clinical specimens. One
additional specimen did not yield a valid DST result for
the evaluation of phenotypic MOX resistance. Four hun-
dred fifty-four (40 %) of the 1128 patients enrolled in
the study had MDR-TB and 80 (7 %) had XDR-TB, as
determined by MGIT DST results. Thus, 907 results
were available for this analysis (906 for MOX).
Sensitivity and Specificity of Pyrosequencing (PSQ) as
Compared to Phenotypic Testing
PSQ diagnostic performance for each TB treatment drug
in each clinical site is detailed in Table 2.
No major differences in the specificity of the PSQ
assay for the detection of resistance to any antibiotic
were observed between the three sites, with assay speci-
ficity ranging from 94 to 100 % for all drugs in all sites
prior to the addition of the eis promoter. The PSQ assay
did, however, show differences in diagnostic sensitivity
for various drugs between the three sites. For the detec-
tion of INH resistance, as seen in the presence of dis-
tinct 95 % confidence intervals, the assay demonstrated
lower sensitivity in South Africa (71 %) than in either
India (98 %) or Moldova (94 %). For the detection of RIF
resistance, the assay demonstrated lower sensitivity in
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Table 2 Pyrosequencing diagnostic performance by clinical site
India (n = 492) Moldova (n = 226) South Africa (n = 196)
Sensitivity Specificity Agreement Sensitivity Specificity Agreement Sensitivity Specificity Agreement
INH 98 % (0.96–0.99) 97 % (0.90–1) 98 % (0.96–0.99) 94 % (0.88–0.97) 96 % (0.87–0.99) 95 % (0.90–0.97) 71 % (0.53–0.85) 94 % (0.87–0.98) 88 % (0.81–0.93)
RIF 98 % (0.95–0.99) 100 % (0.94–1) 98 % (0.96–0.99) 94 % (0.86–0.98) 100 % (0.92–1) 97 % (0.92–0.99) 77 % 0.54–0.91) 98 % (0.91–1) 94 % (0.87–0.97)
MOX 96 % (0.92–0.98) 96 % (0.92–0.98) 96 % (0.94–0.98) 67 % (0.39–0.87) 100 % (0.97–1) 97 % (0.92–0.99) 82 % (0.48–0.97) 99 % (0.96–1) 98 % (0.94–1)
OFX 96 % (0.93–0.98) 99 % (0.96–1) 97 % (0.95–0.99) 64 % (0.36–0.86) 99 % (0.96–1) 96 % (0.91–0.98) 90 % (0.54–0.99) 99 % (0.96–1) 99 % (0.95–1)
AMK 94 % (0.82–0.98) 100 % (0.98–1) 99 % (0.98–1) 33 % (0.11–0.65) 99 % (0.96–1) 95 % (0.91–0.98) 92 % (0.60–1) 98 % (0.94–0.99) 98 % (0.93–0.99)
KAN 89 % (0.76–0.95) 100 % (0.98–1) 99 % (0.97–0.99) 7 % (0.02–0.18) 99 % (0.95–1) 71 % (0.64–0.77) 92 % (0.60–1) 98 % (0.94–0.99) 97 % (0.94–0.99)
KAN (+eis) 93 % (0.81–0.98) 91 % (0.88–0.94) 91 % (0.88–0.94) 79 % (0.66–0.88) 95 % (0.90–0.98) 90 % (0.85–0.94) 92 % (0.60–1) 98 % (0.93–0.99) 97 % (0.93–0.99)
CAP 94 % (0.81–0.98) 99 % (0.98–1) 99 % (0.97–0.99) 40 % (0.14–0.73) 99 % (0.96–1) 96 % (0.92–0.98) 85 % (0.54–0.97) 98 % (0.94–0.99) 97 % (0.92–0.99)
INH isoniazid, RIF rifampicin, MOX moxifloxacin, OFX ofloxacin, AMK amikacin, KAN kanamycin, CAP capreomycin
G
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South Africa (77 %) than in India (98 %). For the detec-
tion of FQ resistance, the assay demonstrated lower sen-
sitivity in Moldova (64–67 %) than in India (96 %). The
sensitivities of the PSQ assay for the detection of resist-
ance to the injectable drugs varied greatly between the
three sites. The sensitivity of the assay for the detection
of AMK resistance was 94 % in India, 33 % in Moldova,
and 92 % in South Africa. The sensitivity for the detec-
tion of CAP resistance was 94 % in India, 40 % in
Moldova, and 85 % in South Africa. The sensitivity of
the assay for the detection of KAN resistance showed
the greatest variation of all the injectables between the
three sites: 89 % in India, 7 % in Moldova, and 92 % in
South Africa. For the detection of injectable resistance,
our PSQ assay demonstrated lower sensitivity in
Moldova than in India for all drugs, though 95 % confi-
dence intervals overlapped with South African estimates
for all but KAN resistance detection. By far, the most
notable difference in assay sensitivity between the three
sites was for the detection of KAN resistance in
Moldova, where only 7 % (95 % CI 0.02–0.18) of the 57
phenotypically KAN-resistant specimens were found to
have the rrs 1401G mutation, compared to 89 % in India
and 92 % in South Africa.
KAN resistance upon eis promoter addition
Prior to the addition of eis promoter sequencing capabil-
ities to the PyroMark platform, overall sensitivity of the
PSQ assay was lowest for the overall detection of KAN
resistance (50.4 %) [11]. The addition of eis promoter
mutations as predictors of KAN resistance increased the
sensitivity estimate to 85.8 %, but decreased overall speci-
ficity for KAN from 99.3 to 93.3 %. In India, the addition
of the eis promoter region to the assay increased test sen-
sitivity for KAN resistance from 89 to 93 %, but decreased
test specificity from 100 to 91 %. The addition of the eis
promoter greatly increased test sensitivity for KAN resist-
ance in Moldova, from 7 to 79 %, but decreased test speci-
ficity from 99 to 95 %. In South Africa, test sensitivity
remained unchanged upon the addition of eis promoter
sequencing capabilities, as no eis promoter mutations
were identified in South African specimens.
Pyrosequencing (PSQ) success by smear- and culture-result
PSQ of the IS6110, katG, inhA, ahpC, gyrA, rrs, and two
rpoB gene targets (regions outlined in Table 1) was per-
formed on all samples, regardless of culture- and smear-
status, at the respective clinical sites. Altogether, 9016
gene target regions were pyrosequenced between the
three sites. Overall, 86.7 % of all smear-positive speci-
mens and 86.4 % of all culture-positive specimens
yielded valid PSQ reads, while 54.9 % of all smear-
negative specimens and 43.1 % of all culture-negative
specimens gave valid sequence reads for the given gene
targets. Figure 1 summarizes PSQ reaction success for
each target gene region, stratified by smear- and culture-
result. The IS6110 gene marker had the highest fre-
quency of successful PSQ reactions for all reactions, at
88 %, followed by inhA, katG, ahpC, rrs, gyrA, rpoB2,
and finally rpoB1 at 85, 83, 81, 80, 71, 69, and 67 %, re-
spectively (Additional file 1: Table S1). In this study,
5493/6144 (89.4 %) of PSQ reactions performed on cul-
ture- and smear-positive specimens and 500/1240
(40.3 %) of PSQ reactions performed on culture- and
smear-negative specimens gave valid sequencing results.
For smear-negative, culture-positive samples, 821/1160
reactions (70.3 %) provided useable sequence informa-
tion, and for culture-negative, smear-positive samples,
234/464 (50.4 %) reactions provided valid sequencing
results (Additional file 1: Table S2).
Pyrosequencing (PSQ) indeterminate analysis
Results of the logistic regression analysis evaluating the
variables associated with poor PSQ technical perform-
ance (PSQ indeterminate results) are displayed in
Table 3. Multivariate logistic regression analysis showed
that independent factors highly associated (adj OR > 2.0)
with poor PSQ technical performance (indeterminate re-
sults) were: culture negativity (adj OR = 7.74), sequen-
cing of either of two rpoB gene targets (adj OR = 5.29
and 4.65), sequencing of gyrA (adj OR = 4.07), sequen-
cing in a Moldovan (adj OR = 2.86) site, sequencing of
the rrs gene target (adj OR = 2.24), and AFB smear nega-
tivity (adj OR = 2.19). Sequencing in a South African site
and sequencing of any gene target other than the IS6110
marker were also significantly associated with increased
odds of sequencing failures, adjusting for other covari-
ates, though at lower levels than for the other variables
(adj OR < 2.0).
The number and type of errors observed for each PSQ
gene target are shown in Table 4. No read errors were
the most commonly occurring error for any gene target
(49-91 % of all indeterminate PSQ reactions). The gyrA
gene target had the highest percentage of no read errors
(91 %) of any gene target. Homopolymer errors were a
common cause of PSQ indeterminate results for the
katG target (40 % of all indeterminate reactions). Instru-
ment errors, mixed populations, and new mutations
made up a minority of PSQ indeterminate calls for any
gene target.
Discussion
Our investigation into the diagnostic and technical per-
formance of PSQ in the GCDD study demonstrated the
following: 1) The PSQ assay showed differences in diag-
nostic performance between clinical sites, especially with
regards to the sensitivity of the assay in detecting KAN
resistance in Moldova, 2) As an open sequencing
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platform, new gene targets may be added to the PSQ
assay to improve diagnostic performance and accommo-
date our evolving knowledge of the molecular basis of
TB drug resistance, and 3) The current PSQ assay proto-
cols may be further improved by optimizing primers and
PCR and sequencing parameters for each gene target in-
cluded in the assay in order to decrease the number of
indeterminate PSQ results. As this PSQ assay has great
potential to curb the spread of M/XDR-TB, and its per-
formance has recently been validated in a large multisite
study, these results have important implications for
future assay use and performance in diverse clinical
environments while highlighting key areas for assay
optimization.
Pyrosequencing diagnostic performance between sites
Differences in diagnostic sensitivity were noted for vari-
ous drug compounds between the three clinical sites.
South Africa showed lower sensitivity for the detection
of INH resistance (71 %, 95 % CI 0.53-0.85) than India
or Moldova, as the PSQ assay did not detect resistance-
associated mutations in 25 of 35 phenotypically INH-
resistant specimens evaluated in South Africa. This
result suggests that these strains do not to have the ex-
pected katG, inhA, and/or ahpC mutations found in ap-
proximately 94 % of INH-resistant strains, globally [22].
One reason for this discordance might be the failure of
our assay to include additional gene regions associated
with INH resistance, such mutations in the fabG1 gene
or outside regions of katG [23, 24], including katG mu-
tations at codons 139, 142, 269, 385, 387 and 541, re-
cently associated with high INH minimum inhibitory
concentrations (>10 μg/mL) [24]. If any of these muta-
tions are common in the South African population
enrolled in our study, then it may be worthwhile to in-
corporate one or more of these gene regions into the
next version of our PSQ assay. However, as only 35
Table 3 Multivariate logistic regression model of variables
associated with poor pyrosequencing technical performance
Variable Crude OR 95 % CI Adjusted OR 95 % CI
AFB Smear
Negative 5.30 4.76–5.90 2.19 1.91–2.51
Positive 1.00 1.00
Culture
Negative 8.44 7.51–9.49 7.74 6.67–8.99
Positive 1.00 1.00
Site
Moldova 2.07 1.84–2.34 2.86 2.47–3.31
South Africa 1.86 1.64–2.10 1.50 1.29–1.74
India 1.00 1.00
Target
katG 1.52 1.19–1.92 1.69 1.29–2.21
inhA 1.30 1.02–1.66 1.38 1.05–1.81
ahpC 1.71 1.35–2.16 1.96 1.50–2.55
rpoB1 3.65 2.93–4.55 5.29 4.12–6.79
rpoB2 3.31 2.65–4.12 4.65 3.62–5.97
gyrA 2.99 2.39–3.73 4.07 3.16–5.23
rrs 1.90 1.50–2.39 2.24 1.72–2.91
IS6110 1.00 1.00
p < 0.01 for all bolded estimates except inhA (p < 0.05)
Fig. 1 Pyrosequencing Technical Performance (Sequencing Success) by Acid-Fast Bacilli Smear and Culture Result
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phenotypically INH-resistant South African specimens
were available for analysis, and the confidence intervals
for the calculation included values as high as 85 %, the
low sensitivity estimate we observed may also have been
an artifact of small sample size.
The PSQ assay also demonstrated lower sensitivity for
the detection of RIF resistance in South Africa (77 %,
95 % CI 0.54–0.91) than in India. The assay did not
detect mutations in five of the 22 phenotypically RIF-
resistant samples evaluated in South Africa. As it is
unlikely that these specimens lacked the resistance-
associated rpoB mutations found in approximately 96 %
of all RIF-resistant strains [22], this result was also likely
due to the small sample size of phenotypically RIF-
resistant South African samples available for analysis, as
the confidence intervals for this calculation included
values as high as 91 %. However, it might also be worth
investigating rpoB gene regions outside of those evalu-
ated in this study, to ensure that no rare mutations are
present in these samples in future studies.
For the detection of FQ resistance, PSQ demonstrated
lower sensitivity in Moldova (64–67 %, 95 % CI 0.36–
0.87) than in India. As 93 % of all FQ-resistant strains
have mutations in the gyrA gene region included in our
assay [22], this result was lower than expected. However,
our diagnostic sensitivity measures were in the range of
those reported by Lacoma et al., who reported 40 % sen-
sitivity for detection of OFX resistance and 70.8 % for
the detection of MOX resistance for a PSQ assay includ-
ing the same gyrA gene regions as our study, tested
against strains from Spain and Lithuania [25]. Further-
more, only 14–15 phenotypically MOX- and OFX-
resistant specimens were analyzed in Moldova, which
may have led to a chance oversampling of specimens
missing these common mutations. This possibility is
reflected in the upper limits of the confidence intervals
for this estimate, which include values as high as 87 %.
As with the detection of phenotypic INH and RIF resist-
ance, although the point estimates for the sensitivity of
the detection for phenotypic FQ resistance were lower
in one clinical site, no significant differences could be
confirmed based upon the spread of the confidence in-
tervals surrounding those sensitivity estimates.
For the detection of injectable resistance, our PSQ
assay showed lower sensitivity in Moldova than in India
for all drugs. The sensitivity of the assay for the detec-
tion of CAP resistance in Moldova (40 %, 95 % CI 0.14–
0.73) was lower than expected, as only four of the 10
phenotypically CAP-resistant specimens evaluated in
this site were found to have the expected rrs 1401G mu-
tation, previously documented to occur in 88 % of CAP-
resistant specimens, globally [22]. For the detection of
AMK resistance in Moldova, the assay also demon-
strated lower sensitivity (33 %, 95 % CI 0.11–0.65) than
expected, as only four of 12 phenotypically AMK-
resistant specimens were determined to have the rrs
1401G mutation found in approximately 84 % of all
AMK-resistant specimens, globally [22]. Although these
discordances are likely related to the small sample size
of AMK- and CAP-resistant specimens evaluated in
Moldova, these observed discordances might also result
from the failure of our assay to include additional gene
regions associated with injectable resistance, such as the
rrs 1484T mutation or tlyA mutations [26]. Indeed,
other studies of tests relying upon the rrs 1401G muta-
tion for AMK and CAP resistance detection have re-
ported sensitivities as low as 57 % [27], and so this result
may be worth further investigation. There is also the
possibility that rrs 1401 or 1402 mutations were present
in the specimens, but were missed by our PSQ assay
for some reason, which would call for a closer look
into the ability of PSQ to accurately sequence this
gene region. These specimens are currently being fur-
ther evaluated by whole genome sequencing to iden-
tify the molecular basis of phenotypic injectable
resistance. By far, however, the most notable differ-
ence in observed sensitivity for any injectable between
the sites was for the detection of KAN resistance in
Moldova, where only 7 % (95 % CI 0.02–0.18) of the
57 phenotypically KAN-resistant specimens were found to
have the rrs 1401G mutation, versus 89 % in India and
92 % in South Africa.
Table 4 Indeterminate pyrosequencing results: number and type of errors by gene target
TARGET No Read Error Homopolymer Error Instrument Error Other Error Mixed Population New Mutation TOTAL Error Rate (/1128 reactions)
IS6110 112 (85 %) 12 (9 %) 4 (3 %) 4 (3 %) - - 132 11.7 %
katG 91 (49 %) 74 (40 %) 1 (1 %) 19 (10 %) 1 (1 %) - 186 16.5 %
inhA 121 (73 %) 9 (5 %) 3 (2 %) 29 (17 %) 2 (1 %) 2 (1 %) 166 14.7 %
ahpC 182 (87 %) 13 (6 %) 6 (3 %) 9 (4 %) - - 210 18.6 %
rpoB1 221 (61 %) 76 (21 %) 15 (4 %) 45 (12 %) 1 (0 %) 3 (1 %) 361 32.0 %
rpoB2 269 (78 %) 40 (12 %) 7 (2 %) 28 (8 %) - 1 (0 %) 345 30.6 %
gyrA 294 (91 %) 2 (1 %) 6 (2 %) 18 (6 %) 1 (0 %) 1 (0 %) 322 28.5 %
rrs 149 (66 %) 30 (13 %) - 48 (21 %) - - 227 20.1 %
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Diagnostic performance following eis promoter addition
In Moldova, a high number of specimens showed resist-
ance to KAN but not to the other injectable compounds
(AMK and CAP). This fact is unsurprising, as kanamycin
was widely used for TB treatment in the former Soviet
Union, selecting for resistance to this compound [28, 29].
The high number of KAN-resistant Mtb clinical speci-
mens without rrsmutations in Moldova (n = 53) suggested
that other genes or gene regions were involved in confer-
ring KAN resistance in this site. Upon the addition of eis
promoter sequencing capability to the PSQ assay, a dra-
matic change in sensitivity for KAN resistance detection
was observed in Moldova (7 % to 79 %), confirming the
role of eis promoter mutations in conferring KAN resist-
ance in this population. Notably, the addition of the gene
region to the assay in India also resulted in a sensitivity
improvement for the detection of KAN resistance (89 %
to 93 %). However, the improved sensitivity came at a loss
to assay specificity in both sites for KAN resistance detec-
tion, due to the presence of eis promoter mutations in
KAN-susceptible specimens. In order to comment upon
this discrepancy, 15 KAN-susceptible Indian specimens
confirmed to have eis promoter mutations were subjected
to repeat phenotypic KAN DST at the critical concentra-
tion (2.5 μg/mL). All DST reactions were run in duplicate.
Eleven of the 15 specimens (73 %) showed a resistant
phenotype in at least one of the two duplicate DST runs,
but five of these results were mixed (one run being sus-
ceptible, the other resistant). Four discrepant specimens
were KAN susceptible in both DST runs. These results
underscore the fact that mutations in this gene region
should to be studied further to quantitate their association
with phenotypic KAN resistance, especially as these muta-
tions confer only low-level KAN resistance, which may or
may not be picked up by phenotypic DST at just one
critical concentration (2.5 μg/mL, in our study) [30].
Although these results suggest a reexamination of the crit-
ical concentration to establish KAN phenotypic resistance,
the addition of this gene region into our assay confirms
the adaptability of our molecular diagnostic platform for
diverse clinical environments.
Pyrosequencing (PSQ) technical performance across all sites
A current limitation of PSQ as an M/XDR-TB diagnostic
is its high rate of sequencing failure. In our study, 25 %
of all sequencing reactions failed to generate an inter-
pretable sequencing read [11], with results varying by
specimen smear- and culture-status. The variable most
highly associated with poor PSQ technical performance
was culture negativity, over AFB smear negativity. This
difference is unsurprising as culture is a more sensitive
test for Mtb compared to AFB smear. However, over
40 % of sequencing reactions conducted on smear- and
culture-negative samples still yielded sequencing results.
Although culture-negative samples are generally consid-
ered to be samples in which the Mtb bacteria is not
present, it is likely that our assay was indeed detecting
Mtb DNA, as the primers designed for our assay are
highly specific for Mtb. This DNA may have come from
dead Mtb bacteria present in the samples, which is likely
seen when processing samples from patients previously
treated for TB infections, and so this finding emphasizes
the importance of DR-TB diagnostic results interpret-
ation in the context of patient clinical presentation and
TB treatment history.
The ability of our assay to sequence a large portion of
AFB smear-negative Mtb clinical specimens underscores
the utility of this molecular diagnostic for a diverse
range of clinical samples. Indeed, our 70.8 % sequencing
success for smear-negative, culture-positive specimens is
better than reported for the GeneXpert assay (55 %)
[31]. As many laboratories lack the sterile conditions or
equipment necessary to perform AFB smear, culture and
DST of Mtb, and a large portion of TB infections remain
smear-negative despite clinical and radiological signs of
disease, PSQ presents a valid alternative to conventional
growth-based diagnostic methods [32]. Although the
presence of Mtb DNA does not necessarily confirm the
presence of viable bacteria in a sample (as with culture-
negative samples), PSQ can potentially provide the clin-
ician with information about a portion of smear-negative
infections when a diagnosis is otherwise elusive, as long
as the results are considered in the context of the pa-
tient’s clinical presentation and past and current TB
treatment regimens [33].
In addition to culture and smear result, the proportion
of interpretable sequencing results in our study appeared
to vary significantly by gene. Interestingly, after culture
negativity, sequencing of the rpoB gene target in either
one of two sequencing reactions was the variable with
the highest adjusted odds of sequencing failure. Poor
rpoB sequencing success is likely a result of the higher
order DNA structures present in the Mtb genomic DNA
at this gene region, preventing DNA access and there-
fore resulting in PCR and/or sequencing failure [34]. Al-
though these higher order DNA structures are inherent
to the rpoB gene, their presence might be addressed by
altering PCR and/or sequencing reaction conditions,
such as increasing the melting and extension tempera-
tures during PCR or introducing reaction additives to
prevent the formation of such structures. Additionally,
the two rpoB sequencing products were the longest in
this study. This factor appeared to contribute to the oc-
currence of indeterminate results by increasing the num-
ber of unresolvable homopolymer errors seen in these
reactions [23]. Increasing the number of sequencing re-
actions for a given target, thereby shortening the length
of the sequencing products, may rectify any issues
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related to gene target sequencing length such as seen
with the rpoB gene targets. Sequencing of the gyrA tar-
get had the next highest odds of indeterminate results.
The high number of indeterminate results seen for gyrA
target sequencing reactions appeared to result from
amplification errors, or primer hybridization during
PCR, as the majority of gyrA sequencing errors were
characterized as no read errors. Like rpoB, gyrA might
form stable secondary DNA structures at the PCR tem-
peratures and conditions used for our assay. This factor
may be addressed in future versions of the PSQ assay by
redesigning the gyrA PCR primers for this reaction or by
adjusting PCR temperatures to relax these higher-order
structures. The variable with the next highest odds of se-
quencing failure was sequencing in Moldova. As the
gene regions sequenced by the PSQ assay are highly
conserved among TB strains worldwide [35, 36], it is
highly unlikely that this poor technical performance ob-
served in Moldova is related to the genetics of the TB
specimens in this site. Instead, this association is likely
tied to methodological factors affecting PCR and PSQ in
Moldova versus other sites, such as long delays between
DNA extraction, PCR and sequencing. In our study, the
Moldovan site was known to batch Mtb samples more
than the other two sites, performing PSQ only once a
week- a factor that may explain technical performance
differences between the sites. A final gene target highly
associated with indeterminate results was the rrs gene.
The majority of rrs indeterminate results were classified as
no read errors, indicating potential for PCR and sequen-
cing optimization, similar to the gyrA target. This analysis
highlights important areas for assay technical performance
improvement, and many of these problematic gene targets
may be easily optimized in future versions of the assay.
Conclusions
Although our PSQ assay was generally a high perform-
ing M/XDR-TB diagnostic across three diverse clinical
environments, notable reductions in sensitivity were
identified between the three sites, especially for KAN re-
sistance detection in Moldova. The flexibility of the PSQ
assay allowed us to quickly update the platform when
this performance lapse was identified, improving assay
sensitivity for KAN resistance detection. Additionally,
we found the PSQ assay to generate data for a large propor-
tion of smear-negative samples, comparable to GeneXpert,
and our analysis of the additional variables associated with
poor PSQ technical performance highlighted gene targets
for optimization to further improve the assay’s technical
performance. These results have important implications for
the use and interpretation of PSQ assays as M/XDR-TB
diagnostics, and may serve to inform other molecular M/
XDR-TB diagnostics that interrogate similar gene targets in
clinics across the globe.
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